Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Hamlet BioPharma, the innovative pharmaceutical company currently advancing several phase II trials targeting infectious diseases and cancer, along with an extensive project and patent portfolio, is delighted to announce the nomination of Dr. Elisabeth Parker to its Board of Directors. Dr. Parker's nomination will bring business development, international pharmaceutical industry networks and leadership excellence to the company and strengthen the continued growth of Hamlet BioPharma.
Dr. Elisabeth Parker is currently serving as a Senior Investment Advisor for Healthcare and Life Sciences at Business Sweden, London; a role she has held since October 2022. Dr. Parker has over 20 years of professional experience in R&D, partnership building, and commercialization of translational research in the Health care sector.
Dr. Parker's expertise in business development is illustrated by significant roles, including Director of Business Development at Macrophage Pharma Ltd., as an integral part of the leadership team. Dr. Parker further served as a Business Development Executive at Cancer Research UK's development and commercialization arm, Cancer Research Technology Ltd (CRT),
In addition to these roles, Dr. Parker has contributed expertise as a Non-Executive Director at Arquer Ltd, a cancer diagnostic company, and Azeria Therapeutics Ltd, a firm specializing in cancer therapeutics. Her earlier tenure as Head of Research at KS Biomedix, a UK quoted biopharmaceutical company, saw her leading efforts in developing therapeutic antibodies for cancer and inflammation.
Catharina Svanborg, Chairman of the board of Hamlet BioPharma, expresses great enthusiasm for Dr. Parker's joining of the board, stating, "Dr. Parker's experience and network in the pharmaceutical industry and life sciences sectors will make an invaluable addition to our Board. Her insights and expertise in commercialization and business development will be essential to develop our rich pipeline of molecules into useful treatments."
Dr. Parker is equally excited about this new chapter, commenting, "Joining the Board of Directors at Hamlet BioPharma is a privilege. I look forward to contributing to the company's growth and success, leveraging my experience in healthcare and life sciences to make a meaningful impact. The science behind the new drug candidates is truly impressive and there is a great need for new treatments within cancer and infection"
For further information, please contact:
Catharina Svanborg, Chairman and Founder of Hamlet BioPharma, +46-709 42 65 49
catharina.svanborg@hamletpharma.com
Martin Erixon, CEO Hamlet BioPharma, +46-733 00 43 77
martin.erixon@hamletpharma.com
www.hamletbiopharma.com